Results 221 to 230 of about 1,111,411 (282)

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients With Systemic Lupus Erythematosus: A Multicenter, Open‐Label Trial

Arthritis Care &Research, EarlyView.
Objective This study aimed to characterize the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of subcutaneous belimumab in pediatric patients with active systemic lupus erythematosus (SLE) receiving standard therapy. Methods This single‐arm, multicenter, open‐label trial (GSK study 200908; ClinicalTrials.gov identifier ...
Hermine I. Brunner, Jordi Antón, Inmaculada Calvo‐Penadés, Richard Dimelow, Gerd Horneff, Sylvia Kamphuis, Rebecca Marino, Andre van Maurik, Kirsten Minden, Masaaki Mori, Josephine Ocran‐Appiah, Christel Wilkinson, Yuichi Yamasaki, Deepak Assudani, for the Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO) Network investigators   +14 more
wiley   +1 more source

BAAR: A framework for blockchain-based anonymous and revocable user authentication scheme. [PDF]

PLoS One
Ahmed M, Ahmad A, Zeshan F, Akram S.
europepmc   +1 more source

Robust overlapping covert communication against partialband interference via chaotic multi-tone spread spectrum. [PDF]

Sci Rep
Guo S, Liu D, Fu Y.
europepmc   +1 more source

Experimental data reuploading with provable enhanced learning capabilities. [PDF]

Sci Adv
Mauser MFX, Four S, Predl LM, Albiero R, Ceccarelli F, Osellame R, Petersen P, Dakić B, Agresti I, Walther P.   +9 more
europepmc   +1 more source

State estimator and convolutional neural networks-based fault localization approach for modern grids. [PDF]

Sci Rep
Bhutto JA, Chauhdary ST, Arif S, Niaz A, Alnamasi K, Moinuddin SQ, Alsenan S, Khan MA.   +7 more
europepmc   +1 more source

Active line model identification protection based on characteristic frequency phase for dual-end weakly-fed AC system. [PDF]

Sci Rep
Hou J, Zhang Z, Fan Y, Song G, Wu X.
europepmc   +1 more source

Reply to Letter: “Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring” by Saccà and Pelto Regarding “Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab”

Annals of Clinical and Translational Neurology, EarlyView.
Lea Gerischer, Jutta Schroeder‐Braunstein, Guido Wabnitz, Andreas Meisel   +3 more
wiley   +1 more source

Locally Encoded Secure Distributed Batch Matrix Multiplication. [PDF]

Entropy (Basel)
Jia H, Jia Z.
europepmc   +1 more source